Acute leukemias in children with Down syndrome

Molecular Genetics and Metabolism

Volumn 107, Issue 1-2, 2012, Pages 25-30

  Seewald, Laura ^a   Taub, Jeffrey W ^b   Maloney, Kelly W ^a,c   McCabe, Edward R B ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^c Children's Hospital Colorado   (United States)

Author keywords

Acute lymphoblastic leukemia; Acute megakaryoblastic leukemia; Down syndrome; Transient myeloproliferative disorder

Indexed keywords

ALISERTIB; ANTINEOPLASTIC AGENT; ASPARAGINASE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; RUXOLITINIB; TOFACITINIB; TRANSCRIPTION FACTOR GATA 1; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; DISEASE ASSOCIATION; DOWN SYNDROME; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MYELOPROLIFERATIVE DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TRANSIENT MYELOPROLIFERATE DISORDER; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; HUMANS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MYELOPROLIFERATIVE DISORDERS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84866159638     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.07.011     Document Type: Review

References (73)

1. Parker S.E., Mai C.T., Canfield M.A., Rickard R., Wang Y., Meyer R.E., Anderson P., Mason C.A., Collins J.S., Kirby R.S., Correa A. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res. A. Clin. Mol. Teratol. 2010, 88:1008-1016.
2. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br. J. Haematol. 2000, 110:512-524.
3. Bruwier A., Chantrain C.F. Hematological disorders and leukemia in children with Down syndrome. Eur. J. Pediatr. 2011, [Electronic publication ahead of print].
4. Khan I., Malinge S., Crispino J. Myeloid leukemia in Down syndrome. Crit. Rev. Oncog. 2011, 16:25-36.
5. Klusmann J.H., Creutzig U., Zimmermann M., Dworzak M., Jorch N., Langebrake C., Pekrun A., Macakova-Reinhardt K., Reinhardt D. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008, 111:2991-2998.
6. Malinge S., Izraeli S., Crispino J.D. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 2009, 113:2619-2628.
7. Massey G.V., Zipursky A., Chang M.N., Doyle J.J., Nasim S., Taub J.W., Ravindranath Y., Dahl G., Weinstein H.J. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 2006, 107:4606-4613.
8. Fonatsch C. The role of chromosome 21 in hematology and oncology. Genes Chromosomes Cancer 2010, 49:497-508.
9. Zipursky A. Transient leukaemia-a benign form of leukaemia in newborn infants with trisomy 21. Br. J. Haematol. 2003, 120:930-938.
10. Bull M.J. Health supervision for children with Down syndrome. Pediatrics 2011, 128:393-406.
11. Langebrake C., Creutzig U., Reinhardt D. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin. Padiatr. 2005, 217:126-134.
12. Gamis A.S., Alonzo T.A., Gerbing R.B., Hilden J.M., Sorrell A.D., Sharma M., Loew T.W., Arceci R.J., Barnard D., Doyle J., Massey G., Perentesis J., Ravindranath Y., Taub J., Smith F.O. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood 2011, 118:6752-6759.
13. Cushing T., Clericuzio C.L., Wilson C.S., Taub J.W., Ge Y., Reichard K.K., Winter S.S. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J. Pediatr. 2006, 148:687-689.
14. Taub J.W., Mundschau G., Ge Y., Poulik J.M., Qureshi F., Jensen T., James S.J., Matherly L.H., Wechsler J., Crispino J.D. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood 2004, 104:1588-1589.
15. Wechsler J., Greene M., McDevitt M.A., Anastasi J., Karp J.E., Le Beau M.M., Crispino J.D. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat. Genet. 2002, 32:148-152.
16. Mundschau G., Gurbuxani S., Gamis A.S., Greene M.E., Arceci R.J., Crispino J.D. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 2003, 101:4298-4300.
17. Ahmed M., Sternberg A., Hall G., Thomas A., Smith O., O'Marcaigh A., Wynn R., Stevens R., Addison M., King D., Stewart B., Gibson B., Roberts I., Vyas P. Natural history of GATA1 mutations in Down syndrome. Blood 2004, 103:2480-2489.
18. Hitzler J.K., Cheung J., Li Y., Scherer S.W., Zipursky A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 2003, 101:4301-4304.
19. Cabelof D.C., Patel H.V., Chen Q., van Remmen H., Matherly L.H., Ge Y., Taub J.W. Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome. Blood 2009, 114:2753-2763.
20. Klusmann J.H., Godinho F.J., Heitmann K., Maroz A., Koch M.L., Reinhardt D., Orkin S.H., Li Z. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev. 2010, 24:1659-1672.
21. De Vita S., Mulligan C., McElwaine S., Dagna-Bricarelli F., Spinelli M., Basso G., Nizetic D., Groet J. Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome. Br. J. Haematol. 2007, 137:337-341.
22. Kiyoi H., Yamaji S., Kojima S., Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 2007, 21:574-576.
23. Klusmann J.H., Reinhardt D., Hasle H., Kaspers G.J., Creutzig U., Hahlen K., van den Heuvel-Eibrink M.M., Zwaan C.M. Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. Leukemia 2007, 21:1584-1587.
24. Norton A., Fisher C., Liu H., Wen Q., Mundschau G., Fuster J.L., Hasle H., Zeller B., Webb D.K., O'Marcaigh A., Sorrell A., Hilden J., Gamis A., Crispino J.D., Vyas P. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood 2007, 110:1077-1079.
25. Sato T., Toki T., Kanezaki R., Xu G., Terui K., Kanegane H., Miura M., Adachi S., Migita M., Morinaga S., Nakano T., Endo M., Kojima S., Kiyoi H., Mano H., Ito E. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. Br. J. Haematol. 2008, 141:681-688.
26. Kisseleva T., Bhattacharya S., Braunstein J., Schindler C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002, 285:1-24.
27. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994, 54:4855-4878.
28. Malkin D., Brown E.J., Zipursky A. The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome. Cancer Genet. Cytogenet. 2000, 116:1-5.
29. Klusmann J.H., Li Z., Bohmer K., Maroz A., Koch M.L., Emmrich S., Godinho F.J., Orkin S.H., Reinhardt D. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev. 2010, 24:478-490.
30. Kuhn D.E., Nuovo G.J., Martin M.M., Malana G.E., Pleister A.P., Jiang J., Schmittgen T.D., Terry A.V., Gardiner K., Head E., Feldman D.S., Elton T.S. Human chromosome 21-derived miRNAs are overexpressed in Down syndrome brains and hearts. Biochem. Biophys. Res. Commun. 2008, 370:473-477.
31. Forestier E., Izraeli S., Beverloo B., Haas O., Pession A., Michalova K., Stark B., Harrison C.J., Teigler-Schlegel A., Johansson B. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood 2008, 111:1575-1583.
32. Fong C.T., Brodeur G.M. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet. Cytogenet. 1987, 28:55-76.
33. Borysov S.I., Granic A., Padmanabhan J., Walczak C.E., Potter H. Alzheimer Abeta disrupts the mitotic spindle and directly inhibits mitotic microtubule motors. Cell Cycle 2011, 10:1397-1410.
34. Granic A., Padmanabhan J., Norden M., Potter H. Alzheimer Abeta peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: requirement for tau and APP. Mol. Biol. Cell 2010, 21:511-520.
35. Whitlock J.A. Down syndrome and acute lymphoblastic leukaemia. Br. J. Haematol. 2006, 135:595-602.
36. Smith M., Arthur D., Camitta B., Carroll A.J., Crist W., Gaynon P., Gelber R., Heerema N., Korn E.L., Link M., Murphy S., Pui C.H., Pullen J., Reamon G., Sallan S.E., Sather H., Shuster J., Simon R., Trigg M., Tubergen D., Uckun F., Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J. Clin. Oncol. 1996, 14:18-24.
37. Maloney K., Larsen E., Mattano L., Friedmann A., Devidas M., Nachman J., Raetz E., Winick N., Whitlock J., Hunger S.P., Carroll W.L. Improved toxic mortality rates for children with Down syndrome acute lymphoblastic leukemia (DS-ALL) treated on Children's Oncology Group (COG) trials for standard risk (SR; AALL0331) but not high risk (HR; AALL0232) ALL. Pediatr. Blood Cancer 2011, 56:900.
38. Maloney K.W., Carroll W.L., Carroll A.J., Devidas M., Borowitz M.J., Martin P.L., Pullen J., Whitlock J.A., Willman C.L., Winick N.J., Camitta B.M., Hunger S.P. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood 2010, 116:1045-1050.
39. Pui C.H., Raimondi S.C., Borowitz M.J., Land V.J., Behm F.G., Pullen D.J., Hancock M.L., Shuster J.J., Steuber C.P., Crist W.M., et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J. Clin. Oncol. 1993, 11:1361-1367.
40. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., Loudin M.G., Liu W., Zhang J., Ma J., Coustan-Smith E., Harvey R.C., Willman C.L., Mikhail F.M., Meyer J., Carroll A.J., Williams R.T., Cheng J., Heerema N.A., Basso G., Pession A., Pui C.H., Raimondi S.C., Hunger S.P., Downing J.R., Carroll W.L., Rabin K.R. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat. Genet. 2009, 41:1243-1246.
41. Russell L.J., Capasso M., Vater I., Akasaka T., Bernard O.A., Calasanz M.J., Chandrasekaran T., Chapiro E., Gesk S., Griffiths M., Guttery D.S., Haferlach C., Harder L., Heidenreich O., Irving J., Kearney L., Nguyen-Khac F., Machado L., Minto L., Majid A., Moorman A.V., Morrison H., Rand V., Strefford J.C., Schwab C., Tonnies H., Dyer M.J., Siebert R., Harrison C.J. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114:2688-2698.
42. Bercovich D., Ganmore I., Scott L.M., Wainreb G., Birger Y., Elimelech A., Shochat C., Cazzaniga G., Biondi A., Basso G., Cario G., Schrappe M., Stanulla M., Strehl S., Haas O.A., Mann G., Binder V., Borkhardt A., Kempski H., Trka J., Bielorei B., Avigad S., Stark B., Smith O., Dastugue N., Bourquin J.P., Tal N.B., Green A.R., Izraeli S. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008, 372:1484-1492.
43. Malinge S., Ben-Abdelali R., Settegrana C., Radford-Weiss I., Debre M., Beldjord K., Macintyre E.A., Villeval J.L., Vainchenker W., Berger R., Bernard O.A., Delabesse E., Penard-Lacronique V. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007, 109:2202-2204.
44. Kearney L., Gonzalez De Castro D., Yeung J., Procter J., Horsley S.W., Eguchi-Ishimae M., Bateman C.M., Anderson K., Chaplin T., Young B.D., Harrison C.J., Kempski H., So C.W., Ford A.M., Greaves M. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009, 113:646-648.
45. Gaikwad A., Rye C.L., Devidas M., Heerema N.A., Carroll A.J., Izraeli S., Plon S.E., Basso G., Pession A., Rabin K.R. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br. J. Haematol. 2009, 144:930-932.
46. Blink M., Buitenkamp T.D., van den Heuvel-Eibrink M.M., Danen-van Oorschot A.A., de Haas V., Reinhardt D., Klusmann J.H., Zimmermann M., Devidas M., Carroll A.J., Basso G., Pession A., Hasle H., Pieters R., Rabin K.R., Izraeli S., Zwaan C.M. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia 2011, 25:1365-1368.
47. Loudin M.G., Wang J., Eastwood Leung H.C., Gurusiddappa S., Meyer J., Condos G., Morrison D., Tsimelzon A., Devidas M., Heerema N.A., Carroll A.J., Plon S.E., Hunger S.P., Basso G., Pession A., Bhojwani D., Carroll W.L., Rabin K.R. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia 2011, 25:1555-1563.
48. Hertzberg L., Vendramini E., Ganmore I., Cazzaniga G., Schmitz M., Chalker J., Shiloh R., Iacobucci I., Shochat C., Zeligson S., Cario G., Stanulla M., Strehl S., Russell L.J., Harrison C.J., Bornhauser B., Yoda A., Rechavi G., Bercovich D., Borkhardt A., Kempski H., te Kronnie G., Bourquin J.P., Domany E., Izraeli S. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010, 115:1006-1017.
49. Cario G., Zimmermann M., Romey R., Gesk S., Vater I., Harbott J., Schrauder A., Moericke A., Izraeli S., Akasaka T., Dyer M.J., Siebert R., Schrappe M., Stanulla M. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010, 115:5393-5397.
50. de Vries J.F., Falkenburg J.H., Willemze R., Barge R.M. The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells. Haematologica 2006, 91:912-919.
51. Perry M.J. The Chemotherapy Source Book 2008, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
52. Creutzig U., Diekamp S., Zimmermann M., Reinhardt D. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr. Blood Cancer 2007, 48:651-662.
53. Sorrell A.D., Alonzo T.A., Hilden J.M., Gerbing R.B., Loew T.W., Hathaway L., Barnard D., Taub J.W., Ravindranath Y., Smith F.O., Arceci R.J., Woods W.G., Gamis A.S. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer 2012, [Electronic publication ahead of print].
54. Yazici Y., Curtis J.R., Ince A., Baraf H., Malamet R.L., Teng L.L., Kavanaugh A. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann. Rheum. Dis. 2011, 71:198-205.
55. Verstovsek S., Kantarjian H., Mesa R.A., Pardanani A.D., Cortes-Franco J., Thomas D.A., Estrov Z., Fridman J.S., Bradley E.C., Erickson-Viitanen S., Vaddi K., Levy R., Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 2010, 363:1117-1127.
56. Kim B.H., Jee J.G., Yin C.H., Sandoval C., Jayabose S., Kitamura D., Bach E.A., Baeg G.H. NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3. Mol. Cancer 2010, 9:36.
57. Kim B.H., Oh S.R., Yin C.H., Lee S., Kim E.A., Kim M.S., Sandoval C., Jayabose S., Bach E.A., Lee H.K., Baeg G.H. MS-1020 is a novel small molecule that selectively inhibits JAK3 activity. Br. J. Haematol. 2010, 148:132-143.
58. Carol H., Boehm I., Reynolds C.P., Kang M.H., Maris J.M., Morton C.L., Gorlick R., Kolb E.A., Keir S.T., Wu J., Wozniak A.E., Yang Y., Manfredi M., Ecsedy J., Wang J., Neale G., Houghton P.J., Smith M.A., Lock R.B. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother. Pharmacol. 2011, 68:1291-1304.
59. Kelly K.R., Ecsedy J., Medina E., Mahalingam D., Padmanabhan S., Nawrocki S.T., Giles F.J., Carew J.S. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J. Cell Mol. Med. 2011, 15:2057-2070.
60. Wen J., Silver S., Lewis T., Ponduru S., Dancik V., Goldenson B., Bray M., Carpenter A., Clemons P., Root D., Stern A., Gould R., Crispino J.D. A Kinome shRNA Screen to Identify Pathways That Regulate Megakaryocyte Polyploidization and New Targets for Differentiation Therapy. ASH Annual Meeting Abstracts 2010.
61. Dordelmann M., Schrappe M., Reiter A., Zimmermann M., Graf N., Schott G., Lampert F., Harbott J., Niemeyer C., Ritter J., Dorffel W., Nessler G., Kuhl J., Riehm H. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 1998, 12:645-651.
62. Arico M., Ziino O., Valsecchi M.G., Cazzaniga G., Baronci C., Messina C., Pession A., Santoro N., Basso G., Conter V. Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology. Cancer 2008, 113:515-521.
63. Goto H., Inukai T., Inoue H., Ogawa C., Fukushima T., Yabe M., Kikuchi A., Koike K., Fukushima K., Isoyama K., Saito T., Ohara A., Hanada R., Iwamoto J., Hotta N., Nagatoshi Y., Okamura J., Tsuchida M. Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group. Int. J. Hematol. 2011, 93:192-198.
64. Chessells J.M., Harrison G., Richards S.M., Bailey C.C., Hill F.G., Gibson B.E., Hann I.M. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch. Dis. Child. 2001, 85:321-325.
65. Taub J.W., Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr. Blood Cancer 2005, 44:33-39.
66. Maloney K.W. Acute lymphoblastic leukaemia in children with Down syndrome: an updated review. Br. J. Haematol. 2011, 155:420-425.
67. Takimoto C.H., Calvo E. Principles of oncologic pharmacotherapy. Cancer Management: A Multidisciplinary Approach 2008, 2-3. CMP Healthcare Media LLC, Lawrence, KS. R. Pazdur, L.D. Wagman, K.A. Camphausen, W.J. Hoskins (Eds.).
68. Stock W., Yu D., Sanford B., Lozanski G., Vij R., Byrd J.C., Powell B.L., Wetzler M., Sher D., Edwards C., Kelly M., Richards S.M., Sung C., Malnassy G., Hoke E., Bloomfield C.D., Larson R.A. Alemtuzumab can be Incorporated into Front-line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102) ASH Annual Meeting Abstracts, 51st ASH Annual Meeting and Exposition 2009.
69. Gokbuget N., Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann. Hematol. 2004, 83:201-205.
70. Tibes R., Keating M.J., Ferrajoli A., Wierda W., Ravandi F., Garcia-Manero G., O'Brien S., Cortes J., Verstovsek S., Browning M.L., Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 2006, 106:2645-2651.
71. Thomas D.A., O'Brien S., Kantarjian H.M. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol. Oncol. Clin. North Am. 2009, 23:949-971.
72. Raetz E.A., Cairo M.S., Borowitz M.J., Blaney S.M., Krailo M.D., Leil T.A., Reid J.M., Goldenberg D.M., Wegener W.A., Carroll W.L., Adamson P.C. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J. Clin. Oncol. 2008, 26:3756-3762.
73. Liedtke M., Twist C., Medeiros B., Gotlib J., Berube C., Bieber M., Bhat N., Teng N., Coutre S. Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Haematologica 2012, 97:30-37.